Annual Securities Report — FY2025
What TAUNS Laboratories,Inc. reported for the period from 2025-07-01 to 2026-06-30.
Filed 2026-09-24View the original on EDINET
How much it says
55Typical
What moved here
24named for the first time
Its own wording
81terms
Which filing this is
5/ 5newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The company operates in a single segment, in vitro diagnostic products. In the fiscal year from 1 July 2025 to 30 June 2026, revenue declined year on year, while operating income and ordinary income also decreased. At the same time, capital expenditures associated with the construction of a new plant and the recognition of government subsidies helped limit the decline in net income.
Komori's summary of this document, not the document's own words.55Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
45
Typical
73
Detailed
38
Thin
0
Almost nothing
68
Detailed
55
Typical
100
Very detailed
13
Almost nothing
79
Very detailed
50
Typical
R&D spend11億円Money spent making new things.
Cash left over-90億円Cash from the business, less what went into equipment.
Spent on equipment45億円Plants, machines — things meant to last.
Employees350Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.